Mitant 12.5 mg Capsule: Precision Dosing for Targeted Oncology Care
Are you searching for a reliable Mitant 12.5 mg capsule exporter from India? Ernest Impex, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced multi-kinase inhibitors. We maintain a high-authority, regulatory-compliant supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that critical cancer treatments are delivered with pharmaceutical-grade integrity and efficient global logistics.
Detailed Product Overview: What is Mitant 12.5 mg?
Mitant 12.5 mg capsule is an oral oncology medication containing the active ingredient Sunitinib. Manufactured by Intas Pharmaceuticals Ltd., a global leader in biosimilars and complex generics, Mitant 12.5 mg is the essential titration strength used in targeted therapy. This specific low-dose formulation allows oncologists to precisely manage patient dosage, optimizing therapeutic benefits while minimizing potential side effects.
For international B2B procurement, Mitant 12.5 mg is a vital component of the treatment regimen for advanced solid tumors, often used as part of a personalized dosing schedule (such as a 50 mg total daily dose composed of multiple capsules).
Primary Therapeutic Indications
Mitant 12.5 mg is clinically utilized globally for the following:
Metastatic Renal Cell Carcinoma (mRCC): An advanced treatment for kidney cancer that has spread.
Gastrointestinal Stromal Tumor (GIST): For patients who have not responded to Imatinib or cannot tolerate it.
Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors in patients with unresectable or metastatic disease.
Mechanism of Action: Multi-Pathway Signal Disruption
Mitant 12.5 mg works by interfering with the specific signaling pathways that cancer cells use to grow and form new blood vessels:
Receptor Blockade: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs), specifically targeting the vascular endothelial growth factor receptors (VEGFR-1, -2, -3) and platelet-derived growth factor receptors (PDGFR-Ξ± and -Ξ²).
Anti-Angiogenesis: By blocking the VEGFR pathway, Mitant prevents the tumor from developing the new blood vessels required to "feed" and expand.
Direct Growth Inhibition: It targets KIT (stem cell factor receptor) and FLT3, interrupting the internal signals that drive rapid cell division in gastrointestinal and hematological malignancies.
Precision Titration: The 12.5 mg strength is critical for "Step-Down" or "Step-Up" dosing strategies to ensure patient compliance and safety.
Administration and Clinical Safety
Dosage Protocol: Typically taken once daily. A common cycle for GIST and RCC is 4 weeks on treatment followed by 2 weeks off.
Storage: Store at room temperature (below 30Β°C). Keep the container tightly closed to protect the medication from moisture.
Key Monitoring Parameters:
Blood Pressure: Regular monitoring is required as Sunitinib can cause significant hypertension.
Thyroid Function: Routine screening for hypothyroidism is standard during TKI therapy.
Cardiac Function: Periodic assessment of left ventricular ejection fraction (LVEF) is recommended.
Liver Health: Periodic liver function tests (LFTs) are essential.
Why Source Mitant from Ernest Impex?
Authentic Intas Oncology Exporter: Direct access to genuine Intas Pharmaceuticals inventory, ensuring 100% product authenticity and competitive wholesale pricing.
Global Distribution Authority: We specialize in the complex documentation and cold-chain logistics required for shipping to Washington, London, Bangkok, Canberra, Singapore, and Kingston.
Regulatory Compliance: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary international export permits.
Bulk Supply Stability: We focus on large-scale fulfillment for hospital pharmacies, oncology networks, and regional distributors in 2026.
π Contact Ernest Impex β Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
π Websites:
π§ Email:
π¦ Business Type: Exporter | Bulk Supplier | Distributor
π² WhatsApp: +91 93599 02383
